"There are an enormous amount of people who have complications from this disease. Some people don't get the treatment they need and this disease can lead to amputations and there are way too many of those. It's criminal."

— Tom Clement, president/CEO of Pathway Medical Technologies, discussing the peripheral arterial disease market and his company's newly FDA-approved atherectomy product, "Pathway set to ride Jetstream across emerging PAD market," pp. 1, 9.